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116 Poster Session IIadjusted as needed. Here, we evaluate the pharmacokinetic effects of
concomitant voriconazole administration on blood TAC levels in
27 consecutive allogeneic HSCT recipients (28–64 y; median 55)
in whom pre-emptive dose-modification was used during the first
2 weeks. A total of 170 levels (3–12 per patient; median 5) were
checked between day11 and day116. None of the levels was sub-
therapeutic (\5 ng/mL), and 34 (20%) were .15 ng/mL. 24 of 27
patients required dose-reduction from day 0 to day 11 based on
levels. Each patient required dose-reduction at least twice. An
increase in the dose was needed in only 2 patients after initial
dose-reduction. TAC doses (median, range) on days 0, 7 and 14
were 1.6 (1–2), 0.6 (0.13–1.4), and 0.4 (0.13–1.1) respectively indi-
cating that the median absolute TAC dose, the median TAC mg/
kg dose, and the median per cent TAC dose (100% being the base-
line) declined substantially. However, the median TAC level over
the first 2 weeks remained between 10 and 14.5. It is clear that
lack of pre-emptive dose-reduction would have resulted in TAC
levels climbing steadily. Based on this, we recommend starting
TAC at 0.02–0.022 mg/kg rather than at 0.03 mg/kg if patients
are on concomitant voriconazole, checking levels regularly, and re-
ducing the dose by 30–40% if the 48-h level is 7–10 and by 40–50%
if it is 10–15.314
LOW RELAPSE RATE AFTER ALLOGENEIC-SCT FOLLOWING A MYELOA-
BLATIVE PREPARATIVE REGIMEN WITH FLAMSA CHEMOTHERAPY AND
TOXICITY-REDUCED CONDITIONING IN PATIENTS WITH HIGH RISK
MYELOID MALIGNANCIES AGED 60 YEARS OR OLDER
Schleuning, M.1, Judith, D.1, Heshmat, M.1, Burlakova, I.1, Taube, R.1,
Jedlickova, Z.1, Baurmann, H.1, Kolb, H.-J.2, Schwerdtfeger, R.1. 1Ger-
man Diagnostic Clinic Foundation, Wiesbaden, Germany; 2University of
Munich and GSF Research Center for Environment and Health,Munich,
Germany.
With the introduction of toxicity-reduced conditioning (TRC)
allogeneic stem cell transplantation (allo-SCT) may be considered
also for elderly patients (pts). However, non-myeloablative regi-
mens are associated with a high relapse risk. Our strategy combined
intensive chemotherapy to induce a status of minimal residual dis-
ease, TRC, GVHD prophylaxis with in vivo T-cell depletion and
adjuvant donor lymphocyte transfusions (aDLT). This report sum-
marizes our cumulative experience in a cohort of 45 consecutive el-
derly pts (60–70 y, median 63 y) with myeloid malignancies (18 with
high risk cytogenetics) treated with the FLAMSA-RIC protocol,
consisting of a 4-day course of chemotherapy (AraC 2 g/m2, Fludar-
abine 30 mg/m2 and Amsacrine 100 mg/2) followed by 3 days rest
and TRC with 4Gy TBI, cyclophosphamide and antithymocyte
globuline prior to allo-SCT. The underlying diseases were AML
(de novo n 5 20; sAML n 5 16) or progressive MDS (n 5 8) with
only 5 pts being in CR at the time of transplant. One pt suffered
from CML in refractory myeloid blast crisis. To further reduce tox-
icity TBI was replaced by intravenous Busulfan (8  3.2 mg/kg) in
the last 16 pts. All but one pt received mobilized peripheral blood
stem cells as graft and 9 pts had a sibling and 36 an unrelated donor.
GVHD prophylaxis consisted of Cyclosporine A and MMF. The
procedure as a whole was clearly myeloablative as evidenced by
full donor chimerism at d1 30 in all pts. Engraftment occurred af-
ter 10–48 d (median 18 d). Of 25 eligible pts (being alive and free of
leukaemia at d 1 120) 8 pts actually received aDLT and none of
these relapsed. Despite the high relapse risk we observed only 6
deaths because of recurrent leukaemia. Severe acute GVHD oc-
curred in 20% and the non relapse mortality was 31% with 3 pts dy-
ing from GVHD, 10 from infection and one from cardiac failure.
With a median follow-up of 10 months for surviving pts the Ka-
plan-Meyer procedure estimates a 43% probability of survival at 2
y after transplantation. Although, the follow-up of pts having re-
ceived i.v. Busulfan is rather short there seems to be a strong ten-
dency of further reduced toxicity without increased relapse
incidence in this cohort. Our data support the notion that toxic-
ity-reduced but still myeloablative conditioning followed by allo-
SCT from related or unrelated donors can safely be applied in el-
derly pts with high risk myeloid malignancies and provides an excel-
lent platform for adoptive immunotherapy after induction of
tolerance.315
SIMILAR SURVIVAL AFTER SIBLING VS UNRELATED DONOR ALLOGE-
NEIC STEM CELL TRANSPLANTATION WITH REDUCED INTENSITY CON-
DITIONING
Stein, S., Goldstein, S.C., Smith, J., Luger, S., Loren, A.,
Stadtmauer, E., Schuster, S., Nasta, S., Tsai, D., Perl, A.,
Andreadis, B., Frey, N., Kasner, M., Cole, S., Hinkle, J., Porter, D.L.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Although recent studies have shown comparable survival out-
comes between unrelated donor (URD) and sibling donor stem
cell transplantation in the myeloablative transplant setting, little
comparative data based on donor source is available in the setting
of non-myeloablative/reduced intensity conditioning (RIC), where
it is presumed that GvL effects must play a key role in long term sur-
vival. In this retrospective analysis, we compare the outcome of 111
patients receiving RIC followed by either matched sibling (n 5 65)
or unrelated donor (n 5 46) peripheral blood stem cell (PBSC)
transplantation for hematologic malignancies. All patients were
deemed ineligible for myeloablative conditioning based on institu-
tional standards for age, comorbid disease, and/or prior therapy. All
sibling and 38 of 46 unrelated recipients received A, B, DR matched
grafts. The median recipient age in both cohorts was identical; sib-
ling 52 y (range 12–75 y) and unrelated 52 y (range 29–69 y). Con-
ditioning regimens were primarily fludarabine/cytoxan-based in
both cohorts, with URD recipients skewed toward the addition of
Alemtuzumab pre-transplant (69% URD vs 25% sib), and the use
of TBI 200 for 21/23 myeloma pts. The distribution of diagnoses
was similar between both cohorts in patients with lymphoid malig-
nancies (NHL, HD, CLL n5 66) 34 sib vs 32 URD, and leukemia/
MDS (n5 22), 10 sib vs 12 URD; the diagnosis of myeloma (n5 23)
was skewed toward sibling donors (21 vs 2 URD). Kaplan-Meier es-
timate of overall survival (OS) for all patients at 2 years was 31%. At
a median f/u of 43 weeks in both cohorts, overall survival was nearly
identical (57% sibs; 55% URD). Of note, there was no statistically
significant difference in 2 year OS between sibling and URD recip-
ients (p5 0.25), nor was there a difference in K-M estimates of OS
between sibling and URD recipients when patients with lymphoid
and myeloid disease were analyzed separately. Among expired pa-
tients, there was no difference in the incidence of disease-related
(26/42 sibs vs 18/32 URD) or treatment-related [organ failure,
infection and GvHD] (16/42 sibs vs 14/32 URD) causes of death.
Furthermore, a statistically significant higher proportion of
GvHD-related death among URD patients was not seen. These
data support the pursuit of unrelated donors for RIC transplanta-
tion as an alternative to sibling donors without compromising over-
all survival.316
DEVELOPMENT AND ANTI-BALB.B REACTIVITY OF T CELLS EMERGING
FROM BONE MARROW CELLS TRANSDUCEDWITH A CLONAL TCRVb14-
Jb2.4 SEQUENCE
Appel, M.Y.1, Friedman, T.M.2, Korngold, R.2. 1Thomas Jefferson Uni-
versity, Philadelphia, PA; 2Hackensack University Medical Center,
Hackensack, NJ.
In previous experiments utilizing spectratype-sequencing, we re-
ported a dominant T cell receptor (TCR) Vb14-Jb2.4 sequence
prevalent in the thoracic duct lymphocyte (TDL) population of ir-
radiated BALB. B mice transplanted with C57BL/6 (B6) mouse
bone marrow and CD81 T cells. CD4-dependent CD81 Vb141
T cells mediate lethal graft versus host disease (GVHD) in
a B6/BALB. B transplantation model. Therefore, we wanted to
investigate the alloreactive potential of T cells expressing the partic-
ular isolated TCRb sequence. We harvested bone marrow from 5-
fluorouracil (5-FU) treated TCRb-/- mice. The bone marrow cells
were retrovirally transduced with a construct containing the cDNAs
for Green Fluorescent Protein (GFP) and the specific Vb14-Jb2.4
TCR sequence. The marrow was then used to reconstitute irradi-
ated B6 mice. 20–40% of the peripheral blood mononuclear cells
(PBMC) in these mice were GFP1Vb141, of which greater than
95% were CD41 and 1–4% were CD81. When the marrow was
used to reconstitute MHC II-/- mice, bred to a B6 background,
Poster Session II 117the resulting GFP1Vb141 T cells comprised 3–4% of the PBMC,
but were .98% CD81. These results suggest that while the TCR
on the transduced cells predisposes their development to the CD4
lineage, it does not absolutely preclude CD8 lineage differentiation.
Importantly, GFP1 cells from BALB. B-primed B6 mice, which had
been administered bone marrow cells transduced with the Vb14-
Jb2.4 TCR construct, exhibited anti-BALB. B reactivity in an
IFNg ELISPOT system. On the other hand, GFP1Vb141 T cells
from primed mice receiving marrow cells transduced with a control
vector expressing Vb14-Jb2.3 TCR, did not show anti anti-BALB.
B reactivity. This bone marrow TCR transduction system can be
used to investigate the development and reactivity of T cells ex-
pressing specific TCRb receptors.317
IMPACT OF PROPHYLACTIC RED BLOOD CELL EXCHANGE FOR PREVEN-
TION OF SEVERE IMMUNE HEMOLYSIS IN PEDIATRIC MINOR ABO-MIS-
MATCHED ALLOGENEIC PERIPHERAL BLOOD PROGENITOR CELL
TRANSPLANTATION
Bolotin, E., Rosenthal, J., Pawlowska, A., Falk, P., Wang, S., Hitt, D.,
Friday, J., Forman, S. City of Hope National Medical Center and Beck-
man Research Institute, Duarte, CA.
The presence of minor ABO incompatibility between donor and
recipient is common in allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT). Delayed severe immune hemolysis due
to donor-derived passenger lymphocytes has been reported in mi-
nor and/or bidirectional ABO-mismatched transplants. To evaluate
the impact of RBC exchange procedure in pediatric patients on the
morbidity and outcome we analyzed 29 pediatric cases undergoing
minor ABO-incompatible allo-HSCT from January 2000 to Janu-
ary 2007. First group (RBC exchange) included sixteen patients
who underwent prophylactic red cell exchange. Six patients received
grafts from HLA identical siblings, ten patients – from HLA
matched unrelated donors. Eleven patients received bone marrow
transplant (BMT), five patients received peripheral stem cell trans-
plant (PBSC). Patient’s age was 10 6 5.3 years old.
Second group (No – RBC exchange) included thirteen patients
who did not undergo prophylactic red cell exchange, but the stem
cell product was plasma depleted according to the institutional
guidelines. Six patients received grafts from HLA identical siblings,
three patients from HLA matched unrelated donors, and four pa-
tients form unrelated cord blood. Four patients received BMT,
five patients received PBSC, four patients received cord blood
transplant. Patient’s age was 7.6 6 5.4 years old.
No incidence of immune mediated hemolysis was documented in
both groups. No patients developed pure red cell aplasia. RBC en-
graftment was not different in both groups (23.26 4.2 vs. 226 4.2
days). Neutrophil engraftment was similar in both groups (21.0 6
5.4 vs. 21.026 4.0 days). No significant difference was found among
the groups in the incidence of acute graft vs. host disease (GVHD).
The incidence of chronic GVHD was insignificantly higher in pa-
tients with no RBC exchange (72% vs. 60%). The relapse rate
and overall outcome were not influence.
In conclusion these results suggest that RBC exchange does not
have a significant impact in pediatric patients. Further investiga-
tions are required to identify the best clinical transfusion practice
in pediatric patients with minor ABO incompatibility.318
BUSULFAN, FLUDARABINE AND TOTAL BODY IRRADIATION FOLLOWED
BY ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
IS AN EFFECTIVE TREATMENT FOR HEMATOLOGIC MALIGNANCIES
WITH ACCEPTABLE TOXICITY IN A HIGHER-RISK POPULATION
Meyers, G., Dunn, A., Kovacsovics, T., Fleming, W., Epner, E., Hayes-
Lattin, B., Mauro, M., Deininger, M., Bubalo, J., Maziarz, R. Oregon
Health and Science University, Portland, OR.Reduced-intensity conditioning regimens followed by allogeneic
peripheral blood stem cell transplantation are a feasible treatment
program for elderly patients with hematologic malignancies and
those who have relapsed after an autologous bone marrow trans-
plant. Optimization of the conditioning regimen to promote disease
control, engraftment, and rapid escalation of donor chimerisms
without compromising treatment-related toxicity was the goal in
our institutional protocol of busulfan 3.2 mg/kg intravenously, flu-
darabine 90 mg/m2, and total body irradiation 200cGy followed by
infusion of allogeneic peripheral blood stem cells. We report the re-
sults of 47 patients treated on this protocol since August 2005. The
treatment cohort included patients with a median age of 62 years
(range 24–74), with 24 patients with myeloid diseases and 23 with
lymphoid diseases. In 14 patients this was a second transplant. Do-
nors included 11 sibling donors and 36 matched unrelated donors
with five with a single-antigen mismatch. At the time of this report,
27 patients are alive, with a median follow-up of 240 days (range 32–
804). Engraftment occurred in all but one patient, and lymphoid
and myeloid donor chimerisms revealed early and stable engraft-
ment. See Table 1 for demographics, chimerism findings, and treat-
ment complications. Kaplan-Meier (K-M) incidence of 1-year non-
relapse mortality was 31% and K-M incidence of relapse was 40%.
The K-M incidence of Grade II-IV Acute GVHD was 71%, with
27.7% Grade III-IV. The K-M incidence of extensive chronic
GVHD was 80%. K-M estimate of long-term overall survival was
36%, with a 1-year survival of 49%. When comparing myeloid vs.
lymphoid diseases, the K-M estimate of long-term progression-
free survival of myeloid diseases was significantly higher at 31%
compared to 19% for lymphoid diseases. In conclusion, our institu-
tional protocol of busulfan, fludarabine and TBI followed by alloge-
neic peripheral blood stem cell transplant shows acceptable toxicity
and overall outcomes in this higher-risk group. Disease relapse sig-
nificantly impacts outcomes in this cohort, and future research will
focus on optimizing disease control.Table 1.Age Mean 60.7 years (range
24–74)Males/Females 33/14
Diseases
AML 20
CML 2
MDS 2
ALL 2
CLL 4
HD 2
MM 4
NHL 9
PLL 1
Waldenstrom’s 1
Previous Auto/Allo 13/1
Sibling Allo/MUD 11/36CD31/CD331
ChimerismsMedianDay1 28 CD31/CD331 79.5%/100%
Day1 56 CD31/CD331 89%/100%
Day1 84 CD31/CD331 90%/100%
Primary Cause of Death N 5 20
Acute GVHD 2
Chronic GVHD 1
Graft Failure 1
Bacterial Infection 2
Fungal Infection 1
Viral Infection 1
Idiopathic Interstitial
Pneumonia1Cardiomyopathy 1
Multiple Organ Failure 1
Recurrent/Persistent
Disease8Thromboembolic 1
